KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Capital Expenditures (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Capital Expenditures for 17 consecutive years, with $45.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 6.76% to $45.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $157.6 million, a 4.83% decrease, with the full-year FY2025 number at $157.6 million, down 4.83% from a year prior.
  • Capital Expenditures was $45.8 million for Q4 2025 at Bio-Rad Laboratories, up from $31.7 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $56.2 million in Q4 2021 to a low of $17.3 million in Q2 2022.
  • A 5-year average of $36.3 million and a median of $35.3 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 38.04% in 2022, then skyrocketed 99.83% in 2023.
  • Bio-Rad Laboratories' Capital Expenditures stood at $56.2 million in 2021, then tumbled by 38.04% to $34.8 million in 2022, then rose by 21.41% to $42.3 million in 2023, then increased by 1.5% to $42.9 million in 2024, then increased by 6.76% to $45.8 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Capital Expenditures are $45.8 million (Q4 2025), $31.7 million (Q3 2025), and $45.7 million (Q2 2025).